Olivia MillerProfessor Richard Scolyer, the Australian pathologist and 2024 Australian of the Year who became the first person in the world to receive an experimental personalised immunotherapy for glioblastoma, has shared a sobering update in 2026: his brain tumour has shown further progression, affecting his cognitive function. Despite the news, Scolyer has maintained a characteristically defiant outlook, writing that "it's not the end of the road and I've got more to do."
His journey — from devastating diagnosis to world-first treatment to recurrence — has reshaped how oncologists think about glioblastoma globally, and raised important questions for every Australian about brain cancer symptoms, treatment options, and when to seek specialist advice.
The Story So Far: A World-First Treatment
In June 2023, Scolyer was diagnosed with a grade 4 glioblastoma IDH wild-type brain tumour — the most aggressive and lethal form of brain cancer, with a median survival of less than 15 months under standard treatment protocols that have remained largely unchanged for the past two decades.
Rather than accept those odds, Scolyer and his longstanding research partner Professor Georgina Long devised a world-first treatment protocol by applying breakthroughs from their melanoma immunotherapy research to his own diagnosis. The treatment combined multiple immunotherapy agents administered before surgical removal of the tumour, followed by further immunotherapy and a personalised cancer vaccine engineered from the genetic profile of his specific tumour cells.
By April 2025, roughly 18 months after diagnosis, Scolyer was cancer-free. The result stunned the international oncology community: no one with his tumour type had achieved comparable outcomes under any known treatment.
The Recurrence and What It Tells Us
In March 2025, scans revealed the cancer had returned. Scolyer was given a prognosis of three months. By the standards of glioblastoma medicine, the fact that he had survived 18 months cancer-free was itself a landmark achievement. The recurrence, while devastating, has not yet ended his fight.
His 2026 update indicates further progression affecting brain functioning — changes he and those close to him have noticed in day-to-day life. Yet he continues to document his journey publicly, providing the research community with real-world data on how glioblastoma responds to novel immunotherapy protocols over time.
For the broader oncology community, each scan, each response, each progression event is a data point. Scolyer himself has stated that his case should be used to help future patients, even if the outcomes are not what anyone hoped.
What This Means for Brain Cancer Research in Australia
The Australian government has committed significant funding to brain cancer research through the Medical Research Future Fund, which has supported glioblastoma trials and personalised oncology programs. Scolyer's case has accelerated interest in combining immunotherapy with personalised tumour vaccines — an approach that is now being pursued in formal clinical trials in Australia and internationally.
The key insight from Scolyer's case is that glioblastoma may not be uniformly resistant to immunotherapy; rather, the timing, combination, and personalisation of treatment could be critical. Most previous immunotherapy trials in brain cancer failed because they were applied as last resorts, when the tumour had already exhausted treatment options. Scolyer's team intervened pre-operatively — treating the immune system before the tumour was removed, priming it to recognise and attack residual cancer cells.
This approach is now being studied in multiple clinical trials. Patients and families facing a glioblastoma diagnosis should ask their oncologist specifically whether pre-operative immunotherapy trials are available and whether tumour sequencing for personalised vaccine development is an option.
Recognising Brain Cancer Symptoms: When to See a Doctor
Glioblastoma is notoriously difficult to catch early because its symptoms overlap with far more common conditions. The speed at which symptoms progress and worsen over days or weeks is the critical differentiating factor.
Key warning signs that warrant urgent medical review include:
- New-onset headaches that are persistent, worsen in the morning, or wake you from sleep
- Unexplained personality or behavioural changes noticed by family members before the person themselves
- Seizures with no prior history of epilepsy
- Progressive weakness on one side of the body, or sudden difficulty with balance
- Speech or language difficulties that develop gradually
- Cognitive changes — difficulty concentrating, memory lapses, problems with word retrieval
None of these symptoms automatically indicates brain cancer — each has numerous more common explanations. But when two or more appear together, or when any single symptom worsens progressively over two to four weeks, the appropriate response is to see a GP for an urgent referral rather than waiting.
A GP who suspects a neurological cause can arrange an MRI scan and, if necessary, a referral to a neurologist or neurosurgeon. Time matters in brain tumour diagnosis: earlier detection gives surgical and oncological teams more options.
Finding Expert Support
A glioblastoma diagnosis is devastating for patients and families alike. Navigating the oncology system — understanding treatment trials, interpreting scan results, asking the right questions of specialists — is overwhelming. Expert Zoom connects Australians with experienced medical professionals, including GPs and specialists who can help you understand a diagnosis, evaluate treatment options, or simply find clarity in a complex medical situation.
Scolyer's public journey has done something rare in medicine: it has made one of the most feared cancer diagnoses feel, if not conquerable, then at least worth fighting. His research legacy will outlast the disease itself.
Medical disclaimer: This article provides general information only and does not constitute medical advice. If you have symptoms of concern, consult a qualified medical professional as soon as possible. Always seek advice from your doctor or a qualified health provider regarding any medical condition.
